PTC/SB/25 (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB Control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) 2815-0445PUS1
In re Application of: Thomas J. JENTSCH	2010 01101 001
Application No.: 10/622,377-Conf. #9926	
Filed: July 18, 2003	
For: TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN PARTICULAR ACTIVE COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS	
The owner*, Thomas J. JENTSCH percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/623,150, filed on July 18, 2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application, and is patent of any patent on the pending reference application, and is patent of any patent on the pending reference application, and is patent or the pending reference application, and is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by any terminal disclaimer filed prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The updersigned is an attorney or agent of record. Reg. No. 40,069	0.7.
Alunny & Reg No. 28977	DEC 1 9 2008
Signature	Date
MaryAnne Armstrong, Ph.D.	
Typed or printed name	(703) 205-8000
	Telephone Number
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card informationand authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	